Among the combinations that are being investigated for NSCLC patients in early phase clinical trials, combination of MEK inhibitor, binimetinib, and anti-PD-1 agent, pembrolizumab, is under investigation in a Phase I/Ib study in advanced NSCLC (NCT03991819) and triple combination of MEK inhibitor, selumetinib, and tremelimumab (anti-CTLA-4) and durvalumab (anti-PD-L1) has been proposed by a single center, investigator-initiated Phase I/II clinical trial [20]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.